These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 22883000

  • 1. [Influence of long-term highly active antiretroviral therapy on bone mineral density in HIV/AIDS patients].
    Su YB, Xie J, Han Y, Qiu ZF, Li YL, Song XJ, Yu W, Li TS.
    Zhonghua Yi Xue Za Zhi; 2012 May 08; 92(17):1155-8. PubMed ID: 22883000
    [Abstract] [Full Text] [Related]

  • 2. [The impact of highly active antiretroviral therapy on bone mineral density in human immunodeficiency virus infected patients].
    Guo FP, Yu XB, Luo L, Han Y, Qiu ZF, Zuo LY, Li YL, Yu W, Li TS.
    Zhonghua Nei Ke Za Zhi; 2010 Aug 08; 49(8):649-52. PubMed ID: 20979781
    [Abstract] [Full Text] [Related]

  • 3. Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy.
    Madeddu G, Spanu A, Solinas P, Calia GM, Lovigu C, Chessa F, Mannazzu M, Falchi A, Mura MS, Madeddu G.
    Q J Nucl Med Mol Imaging; 2004 Mar 08; 48(1):39-48. PubMed ID: 15195003
    [Abstract] [Full Text] [Related]

  • 4. [The influence of long-term nucleotide reverse transcriptase inhibitors on lipids metabolism in HIV/AIDS patients].
    Su YB, Xie J, Han Y, Qiu ZF, Li YL, Song XJ, Yu W, Li TS.
    Zhonghua Nei Ke Za Zhi; 2012 Nov 08; 51(11):859-62. PubMed ID: 23291022
    [Abstract] [Full Text] [Related]

  • 5. Stable bone mineral density over 6 years in HIV-infected men treated with highly active antiretroviral therapy (HAART).
    Bolland MJ, Grey A, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB, Gamble GD, Reid IR.
    Clin Endocrinol (Oxf); 2012 May 08; 76(5):643-8. PubMed ID: 22040002
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of bone mineral density in Iranian HIV/AIDS patients.
    Badie BM, Soori T, Kheirandish P, Izadyar S, SeyedAlinagh S, Foroughi M, Rostamian A, Mohraz M.
    Acta Med Iran; 2011 May 08; 49(7):460-7. PubMed ID: 21960080
    [Abstract] [Full Text] [Related]

  • 7. Serum leptin and bone metabolism in HIV patients treated with highly active antiretroviral therapy.
    Madeddu G, Spanu A, Chessa F, Calia GM, Lovigu C, Mannazzu M, Falchi A, Sanna D, Mura MS, Madeddu G.
    Q J Nucl Med Mol Imaging; 2009 Jun 08; 53(3):290-301. PubMed ID: 18596668
    [Abstract] [Full Text] [Related]

  • 8. Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia.
    Brown TT, Ruppe MD, Kassner R, Kumar P, Kehoe T, Dobs AS, Timpone J.
    J Clin Endocrinol Metab; 2004 Mar 08; 89(3):1200-6. PubMed ID: 15001610
    [Abstract] [Full Text] [Related]

  • 9. Bone mineral density remains stable in HAART-treated HIV-infected men over 2 years.
    Bolland MJ, Grey AB, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB, Woodhouse AF, Gamble GD, Reid IR.
    Clin Endocrinol (Oxf); 2007 Aug 08; 67(2):270-5. PubMed ID: 17547686
    [Abstract] [Full Text] [Related]

  • 10. BMD is reduced in HIV-infected men irrespective of treatment.
    Amiel C, Ostertag A, Slama L, Baudoin C, N'Guyen T, Lajeunie E, Neit-Ngeilh L, Rozenbaum W, De Vernejoul MC.
    J Bone Miner Res; 2004 Mar 08; 19(3):402-9. PubMed ID: 15040828
    [Abstract] [Full Text] [Related]

  • 11. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
    Conde FA, Sarna L, Oka RK, Vredevoe DL, Rettig MB, Aronson WJ.
    Urology; 2004 Aug 08; 64(2):335-40. PubMed ID: 15302490
    [Abstract] [Full Text] [Related]

  • 12. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors.
    Cazanave C, Dupon M, Lavignolle-Aurillac V, Barthe N, Lawson-Ayayi S, Mehsen N, Mercié P, Morlat P, Thiébaut R, Dabis F, Groupe d'Epidémiologie Clinique du SIDA en Aquitaine.
    AIDS; 2008 Jan 30; 22(3):395-402. PubMed ID: 18195566
    [Abstract] [Full Text] [Related]

  • 13. [Clinical application of alendronate for osteoporosis/osteopenia secondary to hyperthyroidism].
    Yang LJ, Shen FX, Zheng JC, Zhang HL.
    Zhongguo Gu Shang; 2012 Feb 30; 25(2):133-7. PubMed ID: 22577718
    [Abstract] [Full Text] [Related]

  • 14. Different impact of NNRTI and PI-including HAART on bone mineral density loss in HIV-infected patients.
    Madeddu G, Spanu A, Solinas P, Babudieri S, Calia GM, Lovigu C, Mannazzu M, Nuvoli S, Piras B, Bagella P, Mura MS, Madeddu G.
    Eur Rev Med Pharmacol Sci; 2015 Dec 30; 19(23):4576-89. PubMed ID: 26698255
    [Abstract] [Full Text] [Related]

  • 15. Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy.
    Mora S, Sala N, Bricalli D, Zuin G, Chiumello G, Viganò A.
    AIDS; 2001 Sep 28; 15(14):1823-9. PubMed ID: 11579244
    [Abstract] [Full Text] [Related]

  • 16. Osteoporosis in lung transplantation candidates with end-stage pulmonary disease.
    Shane E, Silverberg SJ, Donovan D, Papadopoulos A, Staron RB, Addesso V, Jorgesen B, McGregor C, Schulman L.
    Am J Med; 1996 Sep 28; 101(3):262-9. PubMed ID: 8873487
    [Abstract] [Full Text] [Related]

  • 17. Factors influencing changes in bone mineral density in patients with anorexia nervosa-related osteoporosis: the effect of hormone replacement therapy.
    Legroux-Gerot I, Vignau J, Collier F, Cortet B.
    Calcif Tissue Int; 2008 Nov 28; 83(5):315-23. PubMed ID: 18836675
    [Abstract] [Full Text] [Related]

  • 18. Prevalence and predictors of low bone mineral density and fragility fractures among HIV-infected patients at one Italian center after universal DXA screening: sensitivity and specificity of current guidelines on bone mineral density management.
    Mazzotta E, Ursini T, Agostinone A, Di Nicola AD, Polilli E, Sozio F, Vadini F, Pieri A, Trave F, De Francesco V, Capasso L, Borderi M, Manzoli L, Viale P, Parruti G.
    AIDS Patient Care STDS; 2015 Apr 28; 29(4):169-80. PubMed ID: 25692868
    [Abstract] [Full Text] [Related]

  • 19. Factors associated with low bone mineral density in a Brazilian cohort of vertically HIV-infected adolescents.
    Schtscherbyna A, Pinheiro MF, Mendonça LM, Gouveia C, Luiz RR, Machado ES, Farias ML.
    Int J Infect Dis; 2012 Dec 28; 16(12):e872-8. PubMed ID: 23031418
    [Abstract] [Full Text] [Related]

  • 20. Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients.
    Fernández-Rivera J, García R, Lozano F, Macías J, García-García JA, Mira JA, Corzo JE, Gómez-Mateos J, Rueda A, Sánchez-Burson J, Pineda JA.
    HIV Clin Trials; 2003 Dec 28; 4(5):337-46. PubMed ID: 14583850
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.